![Hero Image](/_next/image?url=%2F_next%2Fstatic%2Fmedia%2Fbanner-two-shape-left.6c4ab631.png&w=3840&q=75)
![Hero Image](/_next/image?url=%2F_next%2Fstatic%2Fmedia%2Fhero-right-top.b8bd1734.webp&w=3840&q=75)
Last updated at 23 hours ago
Director
DIN: 08333875
Rajendra Sarjerao Shinde is currently associated with 1 company in various capacities such as Individual Promoter and Director. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08333875.Rajendra Sarjerao Shinde has previously been associated with 1 company in roles such as Director.Rajendra Sarjerao Shinde is currently involved in 2 different roles. Their most recent position is with AAROGYAVAT PHARMACY PRIVATE LIMITED as a Individual Promoter. The first company Rajendra Sarjerao Shinde was appointed to as a director was AAROGYAVAT PHARMACY PRIVATE LIMITED. Rajendra Sarjerao Shinde has a status of Deactivated. Please verify the details for any specific requirements or conditions.
Rajendra Sarjerao Shinde is currently associated with 1 company in various capacities such as Individual Promoter and Director. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08333875.Rajendra Sarjerao Shinde has previously been associated with 1 company in roles such as Director.Rajendra Sarjerao Shinde is currently involved in 2 different roles. Their most recent position is with AAROGYAVAT PHARMACY PRIVATE LIMITED as a Individual Promoter. The first company Rajendra Sarjerao Shinde was appointed to as a director was AAROGYAVAT PHARMACY PRIVATE LIMITED. Rajendra Sarjerao Shinde has a status of Deactivated. Please verify the details for any specific requirements or conditions.
2
Male
India
Gain instant access to verified contact details.
Current Companies (1)
Current LLPs (0)
Past Companies (1)
1y 3m 8 Months Interval
Company Name | Designation | Date of Appointment |
---|---|---|
AAROGYAVAT PHARMACY PRIVATE LIMITED | Individual Promoter | 16-Jan-2019 |
AAROGYAVAT PHARMACY PRIVATE LIMITED | Director | 04-Apr-2022 |